Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
10:00am, Monday, 04'th Jul 2022 GlobeNewswire Inc.
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
Sanofi Global Health lance la marque Impact® à but non lucratif pour 30 médicaments destinés aux pays à faible revenu
10:00am, Monday, 04'th Jul 2022 GlobeNewswire Inc.
Sanofi Global Health lance la marque Impact® à but non lucratif pour 30 médicaments destinés aux pays à faible revenu
Citigroup's Mexican unit draws bids from Banorte, Santander: Report
07:13am, Wednesday, 29'th Jun 2022
Citigroup Inc.'s C, -1.30% efforts to sell its Citibanamex consumer banking unit in Mexico has drawn bids from Financiero Banorte GBOOY, -1.50% and Banco Santander SA SAN, -1.03% , Reuters reported on
Communiqué de presse: Xenpozyme® (olipudase alpha) approuvé par la Commission européenne – premier et seul traitement du déficit en sphingomyélinase acide
05:30am, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
Xenpozyme® (olipudase alpha) approuvé par la Commission européenne – premier et seul traitement du déficit en sphingomyélinase acide
Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease
05:30am, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease
Communiqué de presse: Nexviadyme® (avalglucosidase alpha), nouveau traitement de référence potentiel de la maladie de Pompe, a été approuvé par la Commission européenne
05:30am, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
Nexviadyme® (avalglucosidase alpha), nouveau traitement de référence potentiel de la maladie de Pompe, a été approuvé par la Commission européenne
Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
05:30am, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
Spain's Santander hires Credit Suisse, Goldman to look at Citibanamex bid - source
03:31am, Tuesday, 28'th Jun 2022
Spain's Santander has hired Credit Suisse and Goldman Sachs to potentially consider a bid for the Citibanamex, Citigroup's retail bank in Mexico, a source familiar with the process said on Tuesday.
Sanofi: Information concerning the total number of voting rights and shares – May 2022
08:57pm, Monday, 27'th Jun 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Sanofi: Informations relatives au nombre de droits de vote et d'actions – MAI 2022
08:57pm, Monday, 27'th Jun 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Mise en ligne du document «Q2 2022 Memorandum for modelling purposes»
05:32am, Friday, 24'th Jun 2022 GlobeNewswire Inc.
Mise en ligne du document
Availability of the Q2 2022 Memorandum for modelling purposes
05:32am, Friday, 24'th Jun 2022 GlobeNewswire Inc.
Availability of the Q2 2022 Memorandum for modelling purposes
Communiqué de presse : Vaccin COVID-19 Bêta de Sanofi-GSK : succès de la première étude d’efficacité contre Omicron
05:29am, Friday, 24'th Jun 2022 GlobeNewswire Inc.
Vaccin COVID-19 Bêta de Sanofi-GSK : succès de la première étude d’efficacité contre Omicron
Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
05:29am, Friday, 24'th Jun 2022 GlobeNewswire Inc.
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
Ray Dalio’s Bridgewater increases short bets against Europe stocks
01:22pm, Thursday, 23'rd Jun 2022 MarketWatch
Ray Dalio’s Bridgewater has amped up his bet against European stocks by some 500%.
